📊

Executive Summary

Phase 3 once-weekly TransCon CNP prodrug for achondroplasia that releases the FGFR3-induced growth brake, with tripled efficacy in combination with TransCon hGH

TransCon_CNP

· TransCon prodrug technology

Phase 3

Target:

Mechanism of Action

Target Biology

No target biology data available.

Clinical Data

No clinical trial data available.

Market Opportunity

Investment Thesis

Combination therapy exceeds historical benchmarks for growth with tripling of efficacy compared to TransCon CNP monotherapy
Well-positioned to be the leader in growth disorders with once-weekly TransCon CNP and TransCon hGH
Complementary mechanisms: TransCon CNP releases the brake enabling GH to accelerate outcomes

Catalysts & Upcoming Events

No catalyst data available.

Data sourced exclusively from public filings, corporate presentations, and published clinical data. For informational purposes only. Not investment advice. Satya Bio does not provide recommendations to buy or sell securities. Terms · Privacy